European Journal of Breast Health
Original Article

Prognostic Significance of Adjuvant Chemotherapy Induced Amenorrhea in Luminal A and B Subtypes

1.

Department of Medical Oncology, Gayrettepe Florence Nightingale Hospital, İstanbul, Turkey

2.

Department of Medical Oncology, Haseki Research and Training Hospital, İstanbul, Turkey

3.

Department of General Surgery, Gaziosmanpaşa Research and Training Hospital, İstanbul, Turkey

4.

Department of Breast Surgery, Istanbul Florence Nightingale Hospital, İstanbul, Turkey

5.

Department of General Surgery, Biruni University, İstanbul, Turkey

6.

Department of Physical Therapy and Rehabilitation, Şişli Florence Nightingale Hospital, İstanbul, Turkey

7.

Department of Medical Oncology, Istanbul University School of Medicine, İstanbul, Turkey

8.

Department of Physical Therapy and Rehabilitation, İstanbul Bilim University, İstanbul, Turkey

Eur J Breast Health 2018; 14: 173-179
DOI: 10.5152/ejbh.2018.3808
Read: 84 Downloads: 14 Published: 24 July 2019

Abstract

 

Objective: In this retrospective study, chemotherapy induced amenorrhea in patients with early stage breast cancer and its effects on survival were investigated.


Materials and Methods
: Two hundred fifty-two patients received adjuvant chemotherapy without ovarian suppression treatment (OST) from 600 premenopausal patients were included in the study. Patients were divided into two groups; with amenorrhea and without, and compared with clinicopathologic features and survival. SPSS version 17 was used.


Results
: Chemotherapy-induced amenorrhea (CIA) was observed in 145 (57.5%) of 252 patients who received no OST during follow-up. The 5-year OS rate of patients with CIA was significantly higher than patients without CIA (p= 0.042, 95.9% vs. 89.7% vs. 158.88 vs. 135.33 months, respectively). In the subgroup analysis, the OS in patients with hormone receptor (+) was significantly higher than in those receptor (-) in patients with CIA (p=0.011, 97.5% vs. 90.9% vs. 162.13 vs. 126.16 months, respectively). The OS was significantly longer in the luminal A molecular subtype than in those with luminal B molecular subtype, in patients with CIA, but the difference was not significant in patients without CIA (p=0.027 vs. p=0.074, respectively).


Conclusion
: As a conclusion; survival advantage of the chemotherapy induced amenorrhea more pronounced with hormone receptor positivity, lymph node involvement, and advanced disease over patients who do not develop amenorrhea. This advantage of amenorrhea development further prolongs survival compared with luminal B in the luminal A molecular subtype.


Cite this article as
: Ordu Ç, Pilancı KN, Alço G, Elbüken F, İner Köksal Ü, İlgun S, Sarsenov D, Aydın AE, Öztürk A, İyigün Erdoğan Z, Ağaçayak F, Çubuk F, Tecimer C, Eralp Y, Duymaz T, Aktepe F, Özmen V. Prognostic Significance of Adjuvant Chemotherapy Induced Amenorrhea in Luminal A and B Subtypes. Eur J Breast Health 2018; 14: 173-179.

Files
EISSN 2587-0831
3